Beraprost: Information from Answers.com

This article needs additional citations for verification.
Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (June 2007)


Beraprost
Systematic (IUPAC) name
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4- methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran- 5-butanoic acid
Identifiers
CAS number	88430-50-6 88475-69-8 (sodium salt)
ATC code	B01AC19
PubChem	5282428
Chemical data
Formula	C₂₄H₃₀O₅
Mol. mass	398.492 g/mol
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Unknown
Half life	35–40 minutes
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status	?
Routes	Oral

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology

As an analogue of prostacyclin PGI₂, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill.

Antithrombotics (thrombolytics, anticoagulants and antiplatelet drugs) (B01)

Antiplatelet drugs

Glycoprotein IIb/IIIa inhibitors	Abciximab • Eptifibatide • Tirofiban

ADP receptor/P2Y₁₂ inhibitors	(Thienopyridines) Clopidogrel • Ticlopidine • Prasugrel

Prostaglandin analogue (PGI2)	Beraprost • Prostacyclin • Iloprost • Treprostinil

COX inhibitors	Acetylsalicylic acid/Aspirin # • Aloxiprin • Carbasalate calcium

Other	Ditazole • Cloricromen • Dipyridamole • Indobufen • Picotamide • Triflusal

Anticoagulants

Vitamin K antagonists
(inhibit II, VII, IX, X)

coumarins: Acenocoumarol • Coumatetralyl • Dicoumarol (Dicumarol) • Ethyl biscoumacetate • Phenprocoumon • Warfarin

1,3-Indandiones: Clorindione • Diphenadione • Phenindione

other: Tioclomarol

Factor Xa inhibitors
(with some II inhibition)

Heparin group/ glycosaminoglycans/ (bind antithrombin)	low molecular weight heparin (Bemiparin, Certoparin, Dalteparin, Enoxaparin, Nadroparin, Parnaparin, Reviparin, Tinzaparin) oligosaccharides (Fondaparinux, Idraparinux) heparinoid (Danaparoid, Sulodexide, Dermatan sulfate)

Direct Xa inhibitors	xabans (Apixaban, Otamixaban, Rivaroxaban)

Direct thrombin (II) inhibitors

bivalent: Hirudin (Bivalirudin, Lepirudin, Desirudin)
univalent: Argatroban • Dabigatran • Melagatran • Ximelagatran

Other

Defibrotide • Ramatroban • Antithrombin III • Protein C (Drotrecogin alfa)

Thrombolytic drugs/
fibrinolytics

plasminogen activators: TPA (Alteplase, Reteplase, Tenecteplase) • UPA (Urokinase, Saruplase) • Streptokinase # • Anistreplase • Monteplase

other serine endopeptidases: Ancrod • Fibrinolysin

Brinase

Non-medicinal

Citrate • EDTA • Oxalate

^#WHO-EM. ^†Undergoing clinical trials, not FDA approved. ^‡Withdrawn from market. ^§Development halted.

v • d • e Medications used in the management of pulmonary arterial hypertension (B01, C02)

Prostacyclin analogues	Beraprost, Epoprostenol, Iloprost, Treprostinil

Endothelin receptor antagonists	Ambrisentan, Bosentan, Sitaxentan

PDE5 inhibitors	Sildenafil, Tadalafil

Adjunctive therapy	Calcium channel blockers, Diuretics, Digoxin, Oxygen therapy, Warfarin

Autacoids, unsaturated fatty acids: Eicosanoids

Precursor

Arachidonic acid

Prostanoids

Prostaglandins (PG) and
analogues

Precursor

H₂

Active

D/J	D₂

E/F	E₂ (Dinoprostone): Enprostil · Sulprostone E₁ (Alprostadil): Misoprostol · Gemeprost F_2α (Dinoprost): Bimatoprost · Carboprost · Latanoprost · Tafluprost · Travoprost · Unoprostone

I	I₂ (Prostacyclin/Epoprostenol): Beraprost · Iloprost · Treprostinil

Thromboxanes (TX)

A₂ · B₂

Leukotrienes (LT)

Precursor	Arachidonic acid 5-hydroperoxide

Initial	A₄ · B₄

SRS-A	C₄ · D₄ · E₄

Nonclassic

Lipoxins (A₄, B₄) · Virodhamine

By function

bronchoconstriction (PGF_2α, TXA₂, LTC₄, LTD₄, LTE₄)

vasoconstriction (PGF_2α, TXA₂, TXB₂) · vasodilation (PGE₂, PGI₂, LTC₄, LTD₄, LTE₄)

platelets: induce (TXA₂) inhibit (PGD₂, PGI₂) · leukocytes: induce (TXA₂, LTB₄) inhibit (PGD₂, PGE₂)

labor stimulation: (PGE₂ (Dinoprostone), PGF_2α (Dinoprost))

see also enzymes

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)

Donate to Wikimedia